These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37800725)

  • 21. Molecular biomarkers of Graves' ophthalmopathy.
    Longo CM; Higgins PJ
    Exp Mol Pathol; 2019 Feb; 106():1-6. PubMed ID: 30414981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Curcumin Suppresses TGF-β1-Induced Myofibroblast Differentiation and Attenuates Angiogenic Activity of Orbital Fibroblasts.
    Yu WK; Hwang WL; Wang YC; Tsai CC; Wei YH
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceruloplasmin regulating fibrosis in orbital fibroblasts provides a novel therapeutic target for Graves' orbitopathy.
    Cao J; Qi X; Wang N; Chen Y; Xie B; Ma C; Chen Z; Xiong W
    J Endocrinol Invest; 2023 Oct; 46(10):2005-2016. PubMed ID: 36849849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model.
    Byeon HJ; Kim JY; Ko J; Lee EJ; Don K; Yoon JS
    PLoS One; 2020; 15(8):e0237015. PubMed ID: 32760098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gypenosides Protect Orbital Fibroblasts in Graves Ophthalmopathy via Anti-Inflammation and Anti-Fibrosis Effects.
    Li H; Ma C; Liu W; He J; Li K
    Invest Ophthalmol Vis Sci; 2020 May; 61(5):64. PubMed ID: 32462203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PERK mediates oxidative stress and adipogenesis in Graves' orbitopathy pathogenesis.
    Ko J; Kim JY; Kyoung Chae M; Jig Lee E; Sook Yoon J
    J Mol Endocrinol; 2021 May; 66(4):313-323. PubMed ID: 33870911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves' Orbitopathy.
    Byeon HJ; Chae MK; Ko J; Lee EJ; Kikkawa DO; Jang SY; Yoon JS
    Invest Ophthalmol Vis Sci; 2023 Aug; 64(11):13. PubMed ID: 37555734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
    van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. YAP/TAZ Are Essential for TGF-β2-Mediated Conjunctival Fibrosis.
    Futakuchi A; Inoue T; Wei FY; Inoue-Mochita M; Fujimoto T; Tomizawa K; Tanihara H
    Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3069-3078. PubMed ID: 30025139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy.
    Rhiu S; Chae MK; Lee EJ; Lee JB; Yoon JS
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):5900-10. PubMed ID: 25159204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves' orbital fibroblasts.
    Tsai CC; Wu SB; Kau HC; Wei YH
    Sci Rep; 2018 May; 8(1):7276. PubMed ID: 29739987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sphingosine-1-phosphate is involved in inflammatory reactions in patients with Graves' orbitopathy.
    Seo Y; Chae MK; Han SA; Lee EJ; Lee JH; Yoon JS
    Inflamm Res; 2017 Jun; 66(6):535-545. PubMed ID: 28364200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disulfiram Exerts Antifibrotic and Anti-Inflammatory Therapeutic Effects on Perimysial Orbital Fibroblasts in Graves' Orbitopathy.
    Wang X; Ye H; Yang S; Sha X; Wang X; Zhang T; Chen R; Xiao W; Yang H
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves' Ophthalmopathy-Derived Orbital Fibroblasts
    Wei YH; Liao SL; Wang SH; Wang CC; Yang CH
    Front Endocrinol (Lausanne); 2020; 11():607968. PubMed ID: 33597925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Effect of Guggulsterone in Primary Cultured Orbital Fibroblasts Obtained From Patients with Graves' Orbitopathy.
    Kim BR; Kim J; Lee JE; Lee EJ; Yoon JS
    Invest Ophthalmol Vis Sci; 2020 Mar; 61(3):39. PubMed ID: 32196098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Astragaloside IV attenuates orbital inflammation in Graves' orbitopathy through suppression of autophagy.
    Li H; Zhang Y; Min J; Gao L; Zhang R; Yang Y
    Inflamm Res; 2018 Feb; 67(2):117-127. PubMed ID: 29127443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterisation of human orbital fibroblasts cultivated from intraconal, nasal and central adipose tissues.
    Kim JA; Ahn D; Kim BY; Choi YJ; Shin HJ; Jang SY
    Br J Ophthalmol; 2021 Feb; 105(2):290-296. PubMed ID: 31488432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Review of Pathophysiology and Therapeutic Strategies Targeting TGF-β in Graves' Ophthalmopathy.
    Chang HH; Wu SB; Tsai CC
    Cells; 2024 Sep; 13(17):. PubMed ID: 39273063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
    Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
    PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signal transducer and activator of transcription 3 as a potential therapeutic target for Graves' orbitopathy.
    Ko J; Kim JY; Kim BR; Lee EJ; Kikkawa DO; Yoon JS
    Mol Cell Endocrinol; 2021 Aug; 534():111363. PubMed ID: 34116129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.